Abstract:Hepatocellular carcinoma (HCC) is one of the most common types of cancer. Despite decades of research efforts, the search for novel biomarkers is still urgently needed for the diagnosis of HCC and the improvement of clinical outcomes. Previous studies of HCC clinical biomarkers have usually focused on serum and urine samples (e.g., serum Alpha-fetoprotein (AFP). However, cellular membrane proteins in lesion tissues are less used in HCC diagnosis. The abnormal expression of membrane glycoproteins in tumor lesions are considered as potential targets for tumor diagnosis and tumor therapies. Here, a lectin array has been employed to screen and identify abnormal glycopatterns and cellular membrane glycans in HCC lesion tissues compared with adjacent non-tumor tissues. We found that there was significantly less expression of Erythrina cristagalli (ECA) lectin binding (Galβ1-3/β1-4) glycans on the cellular membrane of HCC lesion tissues compared with those of adjacent non-tumor tissues. Immunohistochemistry analysis further showed that ECA-binding ability on the membrane proteins of HCC tissues progressively decreased in different tumor-node-metastasis (TNM) stages (stage I to stage III) as the malignancy of liver cancer increased. Receiver operating curve (ROC) analysis showed ECA-binding ability yielding a sensitivity of 85% and specificity of 75%, and a combination of ECA and AFP has better clinical diagnostic efficiency, yielding a sensitivity of 90% and specificity of 85%, than ECA or AFP assay alone. ECA pull-down followed by mass spectrometry further showed that there was significantly less expression of ECA binding membrane catalase (CAT) and prolyl 4-hydroxylase beta polypeptide (P4HB) in HCC tissues compared with the adjacent non-tumor tissues. The abnormally increased expression of total CAT and P4HB and decreased expression of galactosylated membrane CAT and P4HB in HCC cell lines were correlated with an HCC metastasis status. Our findings suggest that abnormal declined ECA-binding galatosylated membrane glycans and two galactosylated-CAT and P4HB glycoproteins in lesion tissues are potential biomarkers in the diagnosis and/or metastasis prediction for HCC.

Membrane Protein Glycanprofiling of Hepatocellular Carcinoma Cell with Different Metastastic Potential by Lectin Microarray*

Comparative serum glycoproteomics of non-metastatic and metastatic hepatocellular carcinoma by lectin affinity technology

Lectin-based Glycoproteomics to Explore and Analyze Hepatocellular Carcinoma-Related Glycoprotein Markers.

Identification of N-glycan moiety of tumor marker by lectin microarray

Identification of serum glycobiomarkers for Hepatocellular Carcinoma using lectin microarrays

Glycoprofiling of Early Non-Small Cell Lung Cancer Using Lectin Microarray Technology

Identification and Analysis of Altered Alpha 1,6-Fucosylated Glycoproteins Associated with Hepatocellular Carcinoma Metastasis

Abnormal ECA-Binding Membrane Glycans and Galactosylated CAT and P4HB in Lesion Tissues as Potential Biomarkers for Hepatocellular Carcinoma Diagnosis

Use of Lectin Microarray to Differentiate Gastric Cancer from Gastric Ulcer.

Comparison of the methods for profiling N-glycans—hepatocellular carcinoma serum glycomics study

Lectin microarrays: a powerful tool for glycan-based biomarker discovery.

Multiplex profiling of glycoproteins using a novel bead-based lectin array.

Identification of Aberrantly Expressed Glycans in Gastric Cancer by Integrated Lectin Microarray and Mass Spectrometric Analyses.

Single cell glycan-linkages profiling for hepatocellular carcinoma early diagnosis using lanthanide encoded bacteriophage MS2 based ICP-MS

Selective Isolation and Analysis of Glycoprotein Fractions and Their Glycomes from Hepatocellular Carcinoma Sera

Identification of N-glycan of Alpha-Fetoprotein by Lectin Affinity Microarray

Investigation on Glycosylation Patterns of Proteins from Human Liver Cancer Cell Lines Based on the Multiplexed Proteomics Technology

Application of Lectin Microarrays for Biomarker Discovery

Glycoproteomics investigation of human hepatocellular carcinoma cell lines

Glycan Profiling Changes of Peripheral Regulatory T Cells in Patients with Hepatocellular Carcinoma

Glycoproteomic Analysis of Tissues from Patients with Colon Cancer Using Lectin Microarrays and Nanolc-Ms/ms.